BioMed Central | Articles which cite: Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.

home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F, MITO Investigators
BMC Cancer 2006, 6:202
[Full text] [PubMed] [Related articles]

printer friendly

to [Help]

PubMed Central articles that cite the above article:

1.	Pegylated liposomal doxorubicin in ovarian cancer. Strother R, Matei D Ther Clin Risk Manag 2009 Jun, 5:639-50 [PubMed Central] [PubMed] [Related articles]

You can also check ISI Web of Science for additional citations (subscription required)

printer friendly

to [Help]